Substitute for form 1449A/PTO							Complete if Known						
Substitute for form 1449AFTO							Application Number		To be Assigned 10/751702				
INFORMATION								Dilution A tassour					
DISCLOSURE							Filing Date		Concurrently Herewith				
STATEMENT BY APPLICANT							First Named Inventor		Tuomanen				
DIMENUM BI MIDIORII								oup Art Unit	To be Assigned 1645				
(Use as many sheets as necessary)								aminer Name	To be Assigned MINNIFIELD				
Sheet	1			of	2			orney Docket Number	044158/273011				
U. S. PATENT DOCUMENTS													
Examiner Initials*	Cite No. <sup>1</sup>		ILS	S. Patent Documer Kind er (if kr		Code	- 1	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	ŀ	es of		
NMM	1	US	US-4,925,673					STEINER et al.	05-15-1990				
NMM	2	us	US-5,013,556					WOODLE et al.	05-07-1991				
MMM	3	US	US-5,284,656					PLATZ et al.	02-08-1994				
NMM	4	US	US-5,451,569					WONG et al.	09-15-1995				
NMM	5	US	US-6,245,335					MASURE et al.	06-12-2001				
NMM	6	US	US-6,291,654				$\perp$	HOSTETTER et al.	09-18-2001				
NMM	7	US	US-6,420,135					KUNSCH et al.	07-16-2002				
MMM	8	ÚS	ÚS-6,503,511					WIZEMANN et al.	01-07-2003				
	,							PATENT DOCUME	ENTS				
Examiner Initials	Cite No.	Off				ment nd Co nowr	ode	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Té		
MMM	9	EP		401,384	1			ISHIKAWA, R.	03-13-1996				
NMM	10	W	0 97/41151				MASURE, H., et al.	11-06-1997	1-53				
NMM	11	W	WO 97/09994				BRILES, D., et al.	03-20-1997	1-28, 40, 53				
MMM	12	W	WO 98/21337		7			HOSTETTER, M., et al.	05-22-1998	1-53			
NMM	13	W	VO 98/18930		0			KUNSCH, C., et al.	05-07-1998	1-53			
NMM	14	W	VO 99/51187		7			TUOMANEN, E., et al.	10-14-1999	1-53			
MMM	15	W	2	99/5126	6			WIZEMANN, T., et al.	10-14-1999	1-53			
							Ol	THER DOCUMENTS					
Examiner Initials		Cita (b		nclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher ity and/or country where published.							Т		
		16		ADJEI et al., "Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers," Pharma Res., 1990, pp. 565-569, Vol. 7.									

Unique citation designation number.

<sup>2</sup> See attached Kinds of U.S. Patent Documents.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				C	Complete if Known							
				Application Number	To be Assigne							
INFORM	IATION	DISCLOSU	JRE	Filing Date	Concurrently 1	Concurrently Herewith Tuomanen						
STATEN	MENT B	Y APPLICA	NT	First Named Inventor	Tuomanen							
				Group Art Unit	To be Assigned To be Assigned							
(Use	as many she	ets as necessary)		Examiner Name								
Sheet 2 of 2			2	Attorney Docket Number 044158/273011								
				OTHER DOCUMENTS								
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (bool magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.										
	17	CUNDELL et al., "Receptor specificity of adherence of Streptococcus pneumoniae to human type-II pneumocytes and vascular endothelial cells in vitro," Micro Pathog., 1994, pp. 361-374, Vol. 17.										
	18	CUNDELL et al., "Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor," Nature, 1995, pp. 435-438, Vol. 377.										
	19	HAMMERSCHMIDT et al, "SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component," Mol. Microbiol., 1997, pp. 1113-1124, Vol. 25.										
	20	IDANPAAN-HEIKKELA I., et al., "Oligosaccharides interfere with the establishment and progression of experimental pneumococcal pneumonia," J. Infect. Dis., 1997, pp. 704-712, Vol. 176.										
	21	LANGER, "New methods of drug delivery," Science, pp. 1527-1533, Vol. 249.										
	22	MALIK et al., "Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity," Exp. Hematol., 1992, pp. 1028-1035, Vol. 20.										
	23	MCDANIEL et al., "Molecular localization of variable and conserved regions of pspA and identification of additional pspA homologous sequences in Streptococcus pneumoniae," .Microb. Pathog., 1992, pp. 261-269, Vol. 13.										
	24	NEWMARK et al., " J. Appl. Biochem., 1982, pp. 185-189, Vol. 4.										
	25	REMINGTON'S PHARMACEUTICAL SCIENCES, 18th ed., 1990, Chap. 89, Mack Publishing Co., Easton, PA.										
	26	RONDA et al., "Biological role of the pneumococcal amidase. Cloning of the lytA gene in Streptococcus pneumoniae," Eur. J. Biochem., 1987, pp. 621-624, Vol. 164.  ROSENOW et al., "Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae," Mol. Microbiol., 1997, p. 819, Vol. 25.										
	27											
	28	SHAPIRO et al., "The protective efficacy of polyvalent pneumococcal polysaccharide vaccine," NJEM, 1991, p. 1453, Vol. 325,										
	29	TUOMANEN et al., "Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria. Rev. Infect Dis., 1986, p. 279, Vol. 8, Suppl. 3.										
	30	TUOMANEN et al., "Microbiological and clinical significance of a new property of defective lysis in clinical strains of pneumococci," J. Infect Dis., 1988, pp. 36-43, Vol. 158.										
	31	TUOMANEN et al., "Pathogenesis of pneumococcal infection," NEJM, 1995, pp. 1280, Vol. 322.										
	32	WEARLY, Crit.	Rev. in	Their Drug Carrier System, 1991, 1	pp. 333, Vol. 8.							
Examiner Signature	/1	N. M. Minnif	ield/	(09/26/2006)	Date Considered	09/26/2006						

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

. . . 3